Please login to the form below

Not currently logged in
Email:
Password:

Ann Barbier joins Translate Bio as its chief medical officer

She will take responsibility for leading the US biotech's clinical R&D

Ann BarbierUS-based biotech Translate Bio has appointed Ann Barbier as its new chief medical officer.

She brings 20 years' of drug discovery and development experience to her new role, which will see her take responsibility for leading all clinical research and development, medical affairs and related functions at Translate Bio.

She said: “With near-term clinical programmes in cystic fibrosis and OTC deficiency, Translate Bio is approaching a critical and exciting time.

“Our platform has the potential to be transformative for patients, and I am incredibly excited about the opportunity to join an experienced management team dedicated to finding innovative treatments in areas of high unmet need.”

Prior to joining Translate Bio, Barbier was vice president of clinical development, rare genetic diseases at Agios Pharmaceuticals, where she led the development programme of a small molecule in rare benign haematological diseases.

She has also served Shire in various roles including global clinical development lead and senior medical director, and her career experience has seen her work at Envivo, Johnson & Johnson and Aventis.

15th November 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...